Skip to main content

Sleep Problems

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Neurim Pharmaceuticals
Neurim PharmaceuticalsIsrael - Tel Aviv
1 program
1
Circadin 2 mgPhase 11 trial
Active Trials
NCT01903681Completed16Est. Apr 2014
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Understanding Sleep Problems in Children With Autism Spectrum DisorderN/A1 trial
Active Trials
NCT00691080Completed58Est. Nov 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Neurim PharmaceuticalsCircadin 2 mg
Oregon TherapeuticsUnderstanding Sleep Problems in Children With Autism Spectrum Disorder

Clinical Trials (2)

Total enrollment: 74 patients across 2 trials

Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Start: Mar 2013Est. completion: Apr 201416 patients
Phase 1Completed
NCT00691080Oregon TherapeuticsUnderstanding Sleep Problems in Children With Autism Spectrum Disorder

Understanding Sleep Problems in Children With Autism Spectrum Disorder

Start: Sep 2007Est. completion: Nov 201158 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.